Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

164.50
-3.8300-2.28%
Volume:787.59K
Turnover:128.85M
Market Cap:22.08B
PE:-46.95
High:167.28
Open:166.24
Low:161.65
Close:168.33
52wk High:191.05
52wk Low:61.00
Shares:134.20M
Float Shares:129.78M
Volume Ratio:0.59
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-99.05
PE(LYR):-49.54

Loading ...

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

GlobeNewswire
·
Jun 15

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

GlobeNewswire
·
Jun 15

Guardant Health CIO Kumud Kalia sells 5,000 common shares worth $652,030.00

Reuters
·
Jun 13

Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says

MT Newswires Live
·
Jun 12

RBC Initiates Guardant Health at Outperform With $185 Price Target

MT Newswires Live
·
Jun 12

U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle

Reuters
·
Jun 12

Guardant Health Inc : RBC Initiates Coverage With Outperform Rating; Target Price $185

THOMSON REUTERS
·
Jun 12

BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte

Reuters
·
Jun 11

Guardant Health Says FDA Approved Guardant360 CDx as Companion Diagnostic for Non-Small Cell Lung Cancer Therapy

MT Newswires Live
·
Jun 11

BUZZ-Guardant Health rises as FDA clears blood test for lung cancer drug use

Reuters
·
Jun 11

Guardant Health announces U.S. FDA approved Guardant360 CDx

TIPRANKS
·
Jun 11

Guardant Health Announces FDA Approval of Guardant360 Cdx as Companion Diagnostic for Boehringer Ingelheim’s Hernexeos®

THOMSON REUTERS
·
Jun 11

Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?

Simply Wall St.
·
Jun 10

Guardant Health Co-CEO Helmy Eltoukhy disposes of common shares worth $12.54 million

Reuters
·
Jun 09

Guardant Health CFO Michael Brian Bell disposes of 2,000 common shares worth $257,240.60

Reuters
·
Jun 09

Guardant Health Inc : Mizuho Raises Target Price to $175 From $135

THOMSON REUTERS
·
Jun 08

Guardant Health director Steve Krognes disposes of 9,294 common shares worth $1.23 million

Reuters
·
Jun 06

Guardant Health Initiated at Buy by Goldman Sachs

Dow Jones
·
Jun 05

Guardant Health initiated with a Buy at Goldman Sachs

TIPRANKS
·
Jun 05

Leerink Partners Reaffirms Their Buy Rating on Guardant Health (GH)

TIPRANKS
·
Jun 05